Association of autoantibodies targeting endothelin type-A receptors with no-reflow in ST-elevation myocardial infarction
Copyright © 2023 Elsevier B.V. All rights reserved..
BACKGROUND AND AIMS: No-reflow (NR), where the coronary artery is patent after treatment of ST-elevation myocardial infarction (STEMI) but tissue perfusion is not restored, is associated with worse outcomes. We aimed to investigate the relationship between autoantibodies activating endothelin-1 receptor type A (ETAR-AAs) and NR after primary percutaneous coronary intervention (PPCI) in STEMI.
METHODS: We studied 50 patients (age 59 ± 11 years, 40 males) with STEMI who underwent PPCI within 6 h after the onset of symptoms. Blood samples were obtained from all patients within 12 h following PPCI for ETAR-AA level measurement. The seropositive threshold was provided by the manufacturer (>10 U/ml). NR was assessed by cardiac magnetic resonance imaging (MVO, microvascular obstruction). As a control group, 40 healthy subjects matched for age and sex were recruited from the general population.
RESULTS: MVO was observed in 24 patients (48%). The prevalence of MVO was higher in patients with ETAR-AAs seropositivity (72% vs. 38%, p = 0.03). ETAR-AAs were higher in patients with MVO (8.9 U/mL (interquartile range [IQR] 6.8-16.2 U/mL) vs. 5.7 U/mL [IQR 4.3-7.7 U/mL], p = 0.003). ETAR-AAs seropositivity was independently associated with MVO (OR 3.2, 95% CI 1.3-7.1; p = 0.03). We identified ≥6.74 U/mL as the best cut-off for prediction of MVO (sensitivity 79%; specificity 65%; NPV 71%; PPV 74%; accuracy 72%).
CONCLUSIONS: The ETAR-AAs seropositivity is associated with NR in STEMI patients. These findings may open up new options in the management of myocardial infarction even if confirmation in a larger trial is needed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:378 |
|---|---|
| Enthalten in: |
Atherosclerosis - 378(2023) vom: 15. Aug., Seite 117179 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tona, Francesco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autoantibodies |
|---|
| Anmerkungen: |
Date Completed 14.08.2023 Date Revised 04.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.atherosclerosis.2023.06.970 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359234070 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359234070 | ||
| 003 | DE-627 | ||
| 005 | 20231226080435.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.atherosclerosis.2023.06.970 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1197.xml |
| 035 | |a (DE-627)NLM359234070 | ||
| 035 | |a (NLM)37422357 | ||
| 035 | |a (PII)S0021-9150(23)05073-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tona, Francesco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of autoantibodies targeting endothelin type-A receptors with no-reflow in ST-elevation myocardial infarction |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.08.2023 | ||
| 500 | |a Date Revised 04.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND AND AIMS: No-reflow (NR), where the coronary artery is patent after treatment of ST-elevation myocardial infarction (STEMI) but tissue perfusion is not restored, is associated with worse outcomes. We aimed to investigate the relationship between autoantibodies activating endothelin-1 receptor type A (ETAR-AAs) and NR after primary percutaneous coronary intervention (PPCI) in STEMI | ||
| 520 | |a METHODS: We studied 50 patients (age 59 ± 11 years, 40 males) with STEMI who underwent PPCI within 6 h after the onset of symptoms. Blood samples were obtained from all patients within 12 h following PPCI for ETAR-AA level measurement. The seropositive threshold was provided by the manufacturer (>10 U/ml). NR was assessed by cardiac magnetic resonance imaging (MVO, microvascular obstruction). As a control group, 40 healthy subjects matched for age and sex were recruited from the general population | ||
| 520 | |a RESULTS: MVO was observed in 24 patients (48%). The prevalence of MVO was higher in patients with ETAR-AAs seropositivity (72% vs. 38%, p = 0.03). ETAR-AAs were higher in patients with MVO (8.9 U/mL (interquartile range [IQR] 6.8-16.2 U/mL) vs. 5.7 U/mL [IQR 4.3-7.7 U/mL], p = 0.003). ETAR-AAs seropositivity was independently associated with MVO (OR 3.2, 95% CI 1.3-7.1; p = 0.03). We identified ≥6.74 U/mL as the best cut-off for prediction of MVO (sensitivity 79%; specificity 65%; NPV 71%; PPV 74%; accuracy 72%) | ||
| 520 | |a CONCLUSIONS: The ETAR-AAs seropositivity is associated with NR in STEMI patients. These findings may open up new options in the management of myocardial infarction even if confirmation in a larger trial is needed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Receptor, Endothelin A |2 NLM | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Endothelins |2 NLM | |
| 700 | 1 | |a Vadori, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Civieri, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Masiero, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Iop, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Antonelli, Giorgia |e verfasserin |4 aut | |
| 700 | 1 | |a Perazzolo Marra, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Bianco, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Cecere, Annagrazia |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenzoni, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Naumova, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Bernava, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Basso, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Plebani, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Cozzi, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Iliceto, Sabino |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Atherosclerosis |d 1970 |g 378(2023) vom: 15. Aug., Seite 117179 |w (DE-627)NLM000087394 |x 1879-1484 |7 nnns |
| 773 | 1 | 8 | |g volume:378 |g year:2023 |g day:15 |g month:08 |g pages:117179 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.atherosclerosis.2023.06.970 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 378 |j 2023 |b 15 |c 08 |h 117179 | ||